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deathThe 2014 International Society for Experimental Hematol-
ogy (ISEH) meeting in Montreal was filled with high-
impact science spanning development, aging, immunity,
cell fate, and leukemia, as well as the role of the niche in
each of these processes. There were old friends and new
faces filling the meeting rooms and dance floors at the
conference. Meeting organizers led by ISEH president-
elect Paul Frenette and president Margaret Goodell brought
together leaders in the field as well as newcomers to present
their most recent and compelling work, which we summa-
rize below.Stem cell niche
Although the 43rd annual ISEH scientific meeting was not a
stem cell niche–specific conference, it gathered some of the
top researchers in the field. The recipients of the prestigious
ISEH awards were Toshio Suda (Donald Metcalf Award)
and Emmanuelle Passegue (Mc Culloch and Till Award),
both of whom have made major contributions to the field
of the stem cell niche.
Professor Suda (Keio University, Tokyo, Japan) has
contributed to the elucidation of the stem cell niche and
establishing the fields of stem cell metabolism and stem
cell aging [1,2]. He developed a single-cell culture system
and found that hematopoietic stem cells (HSCs) use the
glycolytic pathway to reduce oxidative stress. Regarding
aging, he presented data showing that a protein called
POT1 prevents telomere instability; however, its expres-
sion is reduced with age.
Vascular signals are important in the HSC niche. Diana
Ramirez-Bergeron (Case Cardiovascular Research Institute,
Cleveland, OH) provided evidence that the transcriptional
activity of HIF in the endothelium is important to maintain
the vascular niche and respond to stress. Myriam Grunwald
(Haddassah Medical School, Jerusalem, Israel) showed that
ectopic overexpression of VEGF in the liver is sufficient to
establish an active ectopic hematopoietic niche. Ingmar
Bruns (Albert Einstein College of Medicine, New York,
NY) showed that, in addition to the vascular niche,Offprint requests to: Dr. Carolina Abramovich; E-mail: exphem@telus.net
0301-472X/$ - see front matter. Copyright  2014 ISEH - International Society
http:/ /dx.doi.org/10.1016/j .exphem.2014.10.007megakaryocytes adjacent to blood vessels support HSC
quiescence via CXCL4.
The importance of the niche on hematologic disease was
discussed. Simon Mendez-Ferrer gave the New Investiga-
tor’s Lecture, where he presented work from his group
demonstrating alterations to both HSCs and niche in myelo-
proliferative neoplasms (MPNs), challenging the paradigm
of MPN driven solely by mutated HSCs [3]. Andreas
Trumpp (German Cancer Research Center, Heidelberg,
Germany) and Andreas Reinisch (Stanford University,
Stanford, CA) presented different methods to ‘‘humanize’’
mouse models to improve engraftment of human hemato-
poietic stem and progenitor cells (HSPCs) from patients
with myelodysplastic syndrome (MDS) or primary myelo-
fibrosis, respectively [4]. Both groups demonstrated that
engraftment of patient-derived mesenchymal stromal cells
improved the in vivo growth of diseased HSPCs, opening
the doors to understanding niche-HSPC connections in
these difficult-to-model diseases.
To gain insight into niche regulation of HSCs, Linheng
Li (Stowers Institute, Kansas City, MO), presented a tran-
scriptional approach to survey gene expression in various
niche and HSPC compartments. His findings suggest that
different niche locations provide unique sites that maintain
and retain different HSC states, which supports his hypoth-
esis of different HSC populations or pools within the bone
marrow. Recently, Pierre Charbord and Charles Durand
took a systems approach to define the signals from stromal
cells that support or inhibit hematopoiesis [5]. Exploiting
the ability to prospectively isolate phenotypically-defined
adult HSPC populations, Andreas Trumpp and team
(including Daniel Lipka, the 2014 postdoctoral prize
winner) used high throughput transcriptomics, methylo-
mics, and proteomics to generate a comprehensive map of
molecular alterations occurring during fate transitions at
the earliest steps of murine hematopoietic differentiation
[6].
Developmental niches and the pertinent signals for HSC
derivation and expansion were also discussed. Jalal Ahmed
(Albert Einstein College of Medicine) studied the role of
Nestinþ pericytes in fetal liver and proved that these cells
are the gatekeepers of HSC expansion in the fetal liver.
Development
During their inception, HSCs arise from specialized hemo-
genic endothelial cells and are controlled by specific cues.for Experimental Hematology. Published by Elsevier Inc.
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Oxford University, Oxford, UK) led the way by discussing
the importance of extrinsically derived BMP, FGF, and
VEGF on hemogenic endothelium formation [7–9]. Elaine
Dzierzak (University of Edinburgh, Edinburgh, UK) used
highly sensitive RNA-seq to delineate the genes differen-
tially expressed among aortic HSCs, hemogenic endothelial
cells, and nonhemogenic endothelial cells, identifying
GPR56 as a required receptor for hematopoietic cluster
formation. Ann Zovein (University of California, San Fran-
cisco, CA) used a murine model to demonstrate that the
timing of expression of Sox17 and Notch1 is important
for hematopoietic specification because early deletion pre-
vents EHT, whereas later deletion promotes it. Albert Kim
(University of California, San Diego, CA; 2014 student
award winner) explored autonomous and nonautonomous
roles for Notch receptors on HSC formation in a zebrafish
model [10]. Mauricio Cortes (Beth Israel Deaconess Med-
ical Center, Boston, MA) showed that vitamin D3 plays a
dynamic role in HSC formation. The inactive form of
vitamin D affects the vascular niche through downregula-
tion of hedgehog signaling, whereas the active form in-
creases HSC numbers both in zebrafish and in human
CD34þ umbilical cord blood cells. David Traver (Univer-
sity of California, San Diego, CA) showed that the inflam-
matory signal TNFa also plays a role in HSC formation
through downregulation of Notch and nuclear factor kB.
Alaa Arraf (Technicon Israel Institute of Technology, Haifa,
Israel) studied the origins of aortic endothelial cells in the
chick and found that coelomic epithelial-derived cells are
incorporated in the ventral wall of the dorsal aorta and
differentiate into CD45-expressing hematopoietic cells,
suggesting a nonvascular origin for HSCs. Along a similar
vein, Peter Currie’s group recently published their data
demonstrating a replacement of aortic endothelium with
cells derived from the somite that provide a regulatory
niche [11]. These reports suggest that there is still much
to learn about the early origins of HSCs.
The mammalian embryo can also support the autono-
mous generation of other hematopoietic lineages before
the emergence of HSCs. Kathleen McGrath (University of
Rochester, Rochester, NY) demonstrated that yolk sac–
derived Mac1þGr1þ cells circulate from E11.5 and seed
the fetal liver, showing the existence of neutrophilic popu-
lations before the emergence of HSCs. Jim Palis (Univer-
sity of Rochester) demonstrated that lymphoid cells can
arise from the yolk sac independently of erythroid-
myeloid progenitors and showed that an embryo needs
not HSCs, but only erythroid-myeloid progenitors, to sur-
vive until birth. Sten Eirik Jacobsen (University of Oxford,
Oxford, UK) also presented data on the emergence of
lymphoid cells before the emergence of definitive HSCs
[12]. Anna Beaudin (University of California, San Francis-
co) showed that there is a developmentally restricted HSC
population, primarily generating lymphoid cells, that cansupport adult hematopoietic reconstitution but is not nor-
mally present in adults. The emerging data in support of
the earlier formation of populations once thought to only
arise from HSCs, as well as data demonstrating lineage-
biased HSCs in development, call into question the dog-
matic concept of a strict hierarchical structure of hemato-
poiesis [13].
Leaders in the field of pluripotent stem cells and reprog-
ramming presented their most recent work on the genera-
tion of HSCs. Gordon Keller (University of Toronto,
Toronto, Canada) discussed the need to identify and elimi-
nate primitive hematopoietic cells from cultures to reveal
and enrich definitive blood cells [14,15]. For example, ret-
inoic acid and Wnt activators, as well as Activin/Nodal
signaling inhibitors, selectively support the growth of defin-
itive hematopoietic progenitors over primitive counterparts
[16,17]. Pedro Real (GENyO, Granada, Spain) showed that
expression of RUNX1c in human embryonic stem cells is
critical for production of hematopoietic progenitors [18].
Derrick Rossi (Harvard Medical School, Boston, MA)
and George Daley (Harvard Medical School) discussed
strategies to dedifferentiate blood cells toward an HSC-
like state. Derrick Rossi’s group demonstrated the ability
of only six transcription factors to reprogram mature mu-
rine blood cells to functional long term HSCs [19]. Daley’s
group, including Linda Vo, who also presented at the con-
ference, took a similar approach to redirect committed
myeloid progenitors, using Sox4, Myb, ERG, HoxA9, and
RORA to confer self-renewal and engraftability [20]. Sur-
prisingly, there was no overlap in the factors used in the
studies of Rossi and Daley, suggesting that there is more
than one way to confer stemness. Both Rossi and Daley pre-
sented unpublished data about chemical screening ap-
proaches to make HSC out of non-HSCs.
Some scientists are using development to gain insight
into the mechanisms of hematologic disease. Teresa
Bowman (Albert Einstein College of Medicine) presented
data showing that zebrafish with mutated sf3b1, a spliceoso-
mal gene that is often mutated in MDS patients, has dimin-
ished HSC number but also increased DNA damage and
p53 pathway activation. Troy Lund (University of Minneso-
ta, Minneapolis, MN) presented a model to study the effects
of oxidative stress on erythroid cells and showed that tp53
can act as an antioxidant critical for the erythroid response
to pro-oxidants such as napthol [21].
Stem cell fate
Stem cell identity and the instruction of fate specification
are known to be controlled in a precise manner through
transcriptional and epigenetic regulatory circuits, yet many
of the mechanisms are poorly understood.
Two presentations shed light on the mostly unknown
mechanisms of action by which presumably globally-
acting chromatin-remodeling enzymes exert their gene-
specific regulatory function during HSC fate determination.
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showed that two Jumonji domain-containing histone
demethylases have highly specific and opposing functions
in HSCs, which could be exploited for HSC expansion
(stimulating positive regulator Jhdm1f) and leukemia
stem cell-directed therapies (enhancing the activity of nega-
tive regulator Jarid1b) [22]. Julie Lessard (University of
Montreal, Montreal, Quebec, Canada) shared new data that
hematopoietic SWI/SNF-like BAF complex composition is
cell type and stage specific. In quiescent HSCs, the complex
is assembled around the Brahma ATPase; upon entrance
into cell cycle and in leukemic stem cells, Brg1 ATPase
is utilized. Consistently, Brg1 is essential for leukemia
maintenance but is dispensable for the maintenance of
quiescent LT -HSCs [23].
Transcriptional and epigenetic regulation is also associ-
ated with the functional decline of many tissue-specific
stem cells during aging and malignant transformation.
Modeling hematologic myeloid malignancies in mice in
adoptive bone marrow transplantation assays, Toshio Kita-
mura (University of Tokyo, Tokyo, Japan) identified new
therapeutic targets for leukemia patients with c-terminally
truncated ASXL1 [24]. Matilda Billing (Lund University,
Lund, Sweden) showed new insights into the TGFb-medi-
ated regulation of HSC quiescence, involving p57 and GA-
TA2, which may also apply to other malignancies. SCL/
TAL1, which has a central role in T-ALL, was shown to
confer oncogenic activity by inducing self-renewal capacity
in a subset of double-negative thymocytes, thereby convert-
ing them into preleukemic stem cells, as presented by Trang
Hoang (University of Montreal).Stem cell expansion
Currently, bone marrow, peripheral blood, and cord blood
represent the main sources of hematopoietic stem and pro-
genitor cells used clinically to treat a variety of hematologic
diseases. Due to the noninvasive isolation and lower im-
mune matching requirements of cord blood cells, they are
gaining popularity for transplantation, but many banked
cords have insufficient cell numbers. Guy Sauvageau’s
group (University of Montreal) used high throughput chem-
ical screening to identify UM171 as a potent small mole-
cule that expands long term repopulating HSPCs [25].
Jonas Larsson’s group (Lund University) screened for nega-
tive regulators of human HSPC expansion and demon-
strated that diminished cohesins led to HSPC expansion
skewed along the myeloid lineage [26]. These data are
consistent with the suggested role of cohesin mutations in
leukemia and demonstrate the value of in vivo validation
of any expansion approaches to ensure no harm.Leukemia
In 1994, the group of John E. Dick in Toronto provided the
first compelling evidence that only a rare population ofhuman acute myeloid leukemia cells display leukemia-
initiating properties, whereas the bulk of the tumor does
not show significant leukemogenic potential [27]. Two de-
cades later, an impressive wealth of information has been
gained on the existence of cancer stem cells in other solid
malignancies, but numerous basic questions remain unan-
swered. Sean Morrison (Howard Hughes Medical Institute,
Chicago, IL) and Scott Armstrong (Boston Children’s Hos-
pital, Boston, MA) provided a critical assessment of the
progress thus far made in the understanding of the biology
of cancer stem cells. Morrison argued that, although many
acute and chronic myeloid leukemias follow a cancer stem
cell (CSC) model, some solid tumors, such as melanoma,
are uniformly tumorigenic under permissive conditions,
which suggests that cell fate can be viewed as how environ-
ment shapes cellular potential [28]. Armstrong agreed with
the sentiment that not all tumor types follow the cancer
stem cell model, but showed compelling evidence in
CML that differences between CSCs and bulk tumor could
have important therapeutic implications [29]. Since it is still
unclear how generalizable the cancer stem cell model is, we
need to further address the role of CSCs in cancer biology.
Transcription factor dysregulation can be a major
component of cancer initiation. Claus Nerlov (University
of Edinburgh) identified a common molecular signature
of leukemic stem cells transformed by diverse oncogenes
from common myeloid progenitors. Tarik M€or€oy (IRCM,
Montreal, Quebec, Canada) showed that the zinc finger
protein Gfi1 maintains lymphoma development and pro-
gression by blocking the activation of the K372 monome-
thylated p53 [30]. Magali Humbert (University of
Montreal) showed that LMO2 overexpression specifically
influences cell cycle of thymic progenitors, which are tar-
gets of cell transformation in T-ALL and regulates DNA
replication through direct binding (with other replication
proteins) to known origins of replication in hematopoietic
progenitors. Celine Moison (University of Montreal)
demonstrated that E4f1, a binding partner of Tp53, Rb1,
and Bmi1, is a critical regulator of the DNA damage
response via interactions with Chk1. Transcription factors
can also alter metabolism, leading to changes in cell state
and tumorigenicity. Patricia Ernst (Dartmouth Medical
School, Hanover, NH) presented the surprising finding that
the methyltransferase activity of MLL is not required for its
function in hematopoiesis or leukemia [31]. Yoshihiro
Hayashi (Cincinnati Children’s Hospital, Cincinnati, OH)
determined that MDS- or acute myeloid leukemia
(AML)-associated RUNX1 mutations act as cooperating
oncogenes with MLL-PTD and showed that those cells
are uniquely sensitive to inhibition of HIF-1a, which may
guide therapeutic interventions for MDS. Keisuke Ito (Al-
bert Einstein College of Medicine) described his work
showing PML-PPARd-fatty acid oxidation pathway con-
trols asymmetric stem cell division and commitment [32].
Benjamin Ebert (Harvard Stem Cell Institute, Boston,
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for lenalidomide reliant on direct binding to the CRBN-
DDB1 E3 ubiquitin ligase. Lenalidomide’s selective growth
inhibition in multiple myeloma (and likely other B-cell
lymphomas) is mediated by targeted degradation of the
IKZF1 and IZKF3 lymphoid transcription factors that are
essential for the differentiation and survival of plasma cells
[33]. These findings identify the multifaceted role of tran-
scription factors in manipulation of leukemia stem cell
function, with potential therapeutic implications.
The modern era of cancer genomics was well covered at
this meeting, with talks from leaders in the field. As part of
Margaret Goodell’s Presidential Symposium highlighting
use of single-cell technologies, Anthony Green (University
of Cambridge, Cambridge, UK) identified somatic muta-
tions in the endoplasmic reticulum chaperone CALR in
70%–84% of patients with MPNs lacking JAK2 mutations
[34]. He demonstrated that gene dosage (JAK2V617 F)
and order of mutation (TET2/JAK2 vs. JAK2/TET2)
influence disease progression [35]. Timothy Ley (Washing-
ton University Medical School, St. Louis, MO) presented
whole genome sequencing data from 200 AML patients
and identified many important rules of interaction or mutual
exclusion among recurrently mutated genes. He also
showed that many clones were only detectable after treat-
ment. Ravi Majeti (Stanford University) presented a
genomic analysis of highly purified leukemic and residual
normal HSCs from de novo AML patients that supports
the concept of a reservoir of preleukemic HSCs harboring
founder mutations lacking the complete complement of ab-
normalities required to generate AML [36,37]. Lambert
Busque (Ho^pital Maisonneuve-Rosemont, Montreal,
Quebec, Canada) provided evidence that mutations in genes
associated with hematologic cancers, such as TET2, can
occur in aging subjects and may be the elusive early
events in the pathogenesis of these disorders [38]. Connie
Eaves (BC Cancer Agency, Vancouver, British Columbia,
Canada) described her newest work using DNA barcodes
to assess clonal architecture, revealing an even greater di-
versity than previously anticipated in the size, content,
durability and reversible dormancy of clones produced by
normal hematopoietic and mammary cells and their trans-
formed derivatives. In-depth clinical sequencing is required
to identify the genes that are mutated in each sample, but
also to define clonal architecture and how subclones indi-
vidually respond to induction therapy.
Inflammation and immunity
Since the seminal discoveries by Andreas Trumpp and Mar-
garet Goodell’s labs about the effects of interferon (IFN) a
and IFNg, respectively, on HSCs, many groups are studying
the role of inflammatory signaling pathways in HSCs
[39,40]. Katherine King (Baylor College of Medicine,
Houston, TX) showed that myeloid-based HSCs express
higher levels of IFNg and enter cell cycle after stimulationwith IFNg or infection, thus providing a novel way to
discriminate alternate HSC phenotypes. Simon Haas
(DKFZ) showed that an interplay between noncanonical
type I interferon and mTOR pathways activates megakaryo-
cyte transcripts and primes HSCs to megakaryocytic differ-
entiation. Brian Liddicoat (St Vincent’s Institute, Fitzroy,
Victoria, Australia) provided interesting results that a cata-
lytically inactive mutant of ADAR1, which modulates IF-
Na responses, also leads to failed hematopoiesis that can
be rescued by knocking out MDA5. Regulation of IFNg re-
sponses is also important. Fanching Lin (National Cancer
Institute, Frederick, MD) showed that generation of CMP,
GMP and MEP from multipotent progenitors is inhibited
in mice that overexpress IFNg.
Another cytokine, M-CSF, is responsible for myeloid
priming of HSCs under stress conditions. Sandrine Sarrazin
(Centre d’Immunologie de Marseille-Luminy, Marseille,
France) showed that the transcription factor MafB is the
gatekeeper of the myeloid cell fate in HSCs by regulating
the accumulation of Pu.1 [41]. Hao Yuan Kueh (California
Institute of Technology, Pasadena, CA), experimenting with
macrophage and T-cell fate control, showed that developing
macrophages lengthen their cell cycle to promote PU.1
expression, whereas T-cells use Notch signaling to switch
Bcl11 b from an inactive to an active state and thus regulate
cell fate [42].
Another major topic was the role of immune cells in
disease. Josee Hebert (Centre hospitalier de l’Universite
de Montreal, Montreal, Quebec, Canada) elegantly re-
viewed how extracellular vesicles can modulate the hu-
moral autoimmune response and control solid organ
transplants and graft-versus-host disease (GVHD). Toward
modulating GVHD, Marcel Van Der Brink (Memorial
Sloan Kettering Cancer Center, New York, NY) reported
on a regenerative loop in intestines, thymus, and possibly
liver that relies on the production of interleukin 22 from
tissue-specific dendritic cells and can alleviate epithelial
cell damage. In addition, Denis Claude Roy (Ho^pital
Maisonneuve-Rosemont) showed that photosensitizer
dibromorhodamine can be used to eliminate alloreactive
T-cells and prevent GVHD [43]. T cells can also be ex-
ploited in cancer therapies. Michel Sadelain (Memorial
Sloan Kettering Cancer Center) talked about the role of
chimeric antigen receptor–expressing T cells and their
effectiveness in multiple cancers, including CLL, NHL,
and ALL [44–46]. In concert with this notion, Claude Per-
reault (University of Montreal) demonstrated the impor-
tance of the immunopeptidome for combating disease
and explained how important it is to combine proteomic
analysis with transcriptome data [47].
Aging
Aging leads to the generation of more phenotypically
defined but less functionally competent HSCs. The session
on aging explored why this occurs and ways in which aged
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Children’s Hospital; University of Ulm, Ulm, Germany)
presented evidence regarding the role of cell polarity in
HSC function. Young HSCs demonstrate both nuclear and
cytoplasmic polarity with respect to proteins including
Cdc42, tubulin, and AcH4K16 [48]. Geiger postulates that
ageing may be attributed to loss of polarization of epige-
netic marks, such as H4K16 acetylation. Christopher Park
(Memorial Sloan Kettering Cancer Center) reported that
miR125b maintains HSC self-renewal but that its level is
diminished with age. Restoring expression of miR125b in
aged HSCs could reverse age-related phenotypes. To
discover the expression signature of aged HSCs, Monika
Kowalczyk (Broad Institute, Cambridge, MA) reported
studies using single-cell RNAseq of HSCs that revealed dif-
ferences in cell cycle status. Larry Luchsinger (Columbia
University) provided compelling data that identified a novel
molecular switch instructing the differentiation of either
myeloid or lymphoid lineage-primed HSCs through
Prdm16-mediated regulation of mitochondrial dynamics
and calcium homeostasis [49].
Themes of aging, calorie restriction, stress, and cell cycle
regulation were all echoed in Emmanuelle Passegue’s (Uni-
versity of California, San Francisco) lecture as the 2014
recipient of the McCulloch and Till Award. Among her many
contributions to the field of HSC biology, Passegue’s work
has spanned the areas of metabolic and environmental stress,
DNA damage repair, aging, and leukemogenesis [50–52].
Recent work in the Passegue lab indicates that the multipo-
tent progenitor stage of hematopoietic development may be
the critical stage at which lineage commitment first occurs.
Transcriptional differences in these classes of multipotent
progenitors fall into three major components: metabolism,
cell cycle, and inflammation. Further insight into important
stages in differentiation has come through recent in situ
studies of malignant AML clusters showing that proliferation
and differentiation are inversely correlated.Concluding remarks
Many of this meeting’s presentations demonstrated that dis-
secting the mechanisms that instruct cell fate decisions has
become one of the leitmotifs, not only in our investigations
of the fundamentals of normal hematopoiesis, but also in
our quest for successful tissue engineering approaches for
disease modeling and drug testing.
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